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Abstract
Purpose This study aims to determine uveitis specialists’
practice patterns, preferences, and perceptions of corticosteroid-
sparing therapies for the initial treatment of chronic noninfec-
tious uveitis.
Methods A survey was distributed to the American Uveitis
Society and Proctor email listservs in order to restrict the
respondents to specialists who likely have extensive
experience in the use of immunomodulatory therapy. Topics
included effectiveness, usage, and preferences related to
seven immunomodulatory treatments.
Results Among the 45 responders, the majority (59%) had
greater than 10 years of experience treating uveitis.
Methotrexate was the most commonly used initial therapy
for anterior, intermediate, and posterior/panuveitis (85%,
57%, and 37%), and the most preferred for anterior (55%).
Mycophenolate mofetil was the most preferred for inter-
mediate (35%) and posterior/panuveitis (42%). Primary
reasons not to prescribe a treatment were effectiveness for
azathioprine, safety/tolerability for cyclosporine and cyclo-
phosphamide, and a mixture of cost, safety/tolerability, and
difficulty of administration for the biologic drugs.
Conclusions Within the group of highly experienced uveitis
specialists, methotrexate is still the most commonly used
initial treatment. Although newer biologic drugs are seen as
effective, they are not commonly used, or even preferred, as
initial corticosteroid-sparing treatment.
Keywords Uveitis.Treatment.Immunomodulatory
therapy.Corticosteroids.Biologics.Survey
Introduction
Uveitis is a set of conditions characterized by intraocular
inflammation and is a significant cause of vision loss in the
USA and the world [1, 2]. Some forms of acute uveitis may
be effectively treated with short courses of cortico-
steroids. Conversely, uveitis that is determined to be
chronic and non-infectious in nature often requires the
introduction of a corticosteroid-sparing immunomodulatory
treatment in order to control inflammation and avoid
undesirable complications associated with chronic use of
high-dose corticosteroids [3, 4]. Current guidelines recom-
mend starting a corticosteroid-sparing treatment if a dose of
greater than 10 mg of oral prednisone is required
chronically to control inflammation [3].
A number of immunomodulatory therapy classes are
currently used to treat uveitis, including antimetabolites,
calcineurin inhibitors, alkylating agents, and biologic drugs.
With the exception of the antimetabolites methotrexate and
azathioprine, all of these drugs have been introduced in the
last 25 years. Due to the low prevalence of uveitis, new
treatments have historically been integrated into practice as
a result of their success in controlling other autoimmune
inflammatory disorders and subsequent anecdotal evidence
based on small case series published by uveitis specialists.
As collective experience builds, additional evidence has
become available in the form of larger retrospective cohort
studies and a few small clinical trials.
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nomodulatory treatments have been established fairly
recently to aid clinicians in treating uveitis, but they do
not dictate a specific algorithm on how immunomodulatory
therapies should be used [3]. There is little information
available on what treatments are being used as first-line
corticosteroid-sparing agents and the reasons why specific
therapies are not preferred. This survey aims to capture the
practice patterns and perceptions of uveitis specialists
concerning first-line corticosteroid-sparing treatment for
chronic uveitis.
Materials and methods
Survey population
The survey was distributed by email to 205 members of the
American Uveitis Society and Proctor Foundation listservs
through the use of the web application surveymonkey.com.
Thefirstemail,containingalinktothesurvey,wassenton10/
6/09. All responses were anonymous. The American Uveitis
Societyisaselective groupofuveitis specialists.Admissionis
votedonbyanexecutive committee andrequiresapplicantsto
commit at least one third of their time to clinical care and/or
research involving immunology/inflammation, at least two
first or second author publications on immunology/inflamma-
tion in peer-reviewed journals in the last 4 years, and two
letters ofrecommendation, with atleast one froma memberof
the American Uveitis Society. The Proctor Foundation listerv
is comprised of specialists in ocular inflammatory disease.
There is overlap in these two listservs, but each respondent
was only allowed to submit one survey response. This
population was chosen despite its small size in order to elicit
opinions only from uveitis experts who are likely to have
extensive experience with the use of immunomodulatory
therapies as steroid-sparing treatment.
Survey
The survey consisted of five sections and included seven
immunomodulatory therapies: methotrexate, mycopheno-
late mofetil, azathioprine, cyclosporine, cyclophosphamide,
infliximab, and adalimumab. The first section contained
Likert scales for rating the effectiveness of seven therapies
for controlling inflammation and allowing a successful
corticosteroid taper in three anatomical locations of uveitis
(anterior, intermediate, and posterior/panuveitis). Effective-
ness ratings were reported on a four-point Likert scale, with
1 and 2 representing unfavorable responses of “Not
effective” and “Somewhat effective”, and 3 and 4 repre-
senting favorable responses of “Mostly effective” and
“Very effective”. The second and third sections captured
which treatments are most commonly used as first-line
corticosteroid-sparing therapy and which would be pre-
ferred in an ideal world where cost and availability were not
an issue. In these sections, respondents were asked to rank-
order the seven treatments within each anatomic location
according to actual use and preference. The fourth section
had a variety of questions to determine perceived disadvan-
tages of each treatment, as well as more detailed questions
on the administration of methotrexate and what dose levels
of systemic and topical corticosteroids are considered
acceptable maintenance doses. Finally, demographic infor-
mation on the respondents was collected. Institutional
review board exemption was obtained.
Statistical methods
Descriptive analyses were conducted with binomial 95%
confidence intervals where appropriate. Additional analyses
of Likert-style questions were conducted using Kruskal–
Wallis analysis of variance to compare effectiveness of
treatments [5]. P values shown are nominal (16 hypothesis
tests were performed) and only referred to as statistically
significant when the reported value was less than 0.003
according to the Bonferroni correction for multiple compar-
isons. Worth estimates were calculated based on ranking
data using a Bradley–Terry model to represent what fraction
of overall worth could be assigned to each treatment and to
estimate an overall ranking [6]. All analyses were con-
ducted using the statistical software R (www.R-project.org).
Results
Physician demographics and characteristics
Of the 205 clinicians contacted through the listserv, 45
completed the survey. All respondents characterized them-
selves as practicing uveitis specialists, of which the majority
(59%)hadmorethan10yearsofexperience,andanadditional
14% had 6–10 years of experience. Sixty-eight percent of
respondents practice in a university or academic setting, 27%
in a private solo/group practice, and 5% in a health
maintenance organization. Ninety-seven percent prescribe
and manage immunomodulatory therapy themselves at least
someofthetime,with41%reportingthattheyalwaysmanage
such treatment themselves. Eighty-three percent of the
respondents practice in the USA, 6% in Mexico, 6% in
Europe, 3% in Australia, and 3% in Canada.
Treatment effectiveness
Treatment effectiveness was defined as the ability to control
ocularinflammationandsuccessfullytapercorticosteroidstoan
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the median acceptable maintenance dose of oral prednisone
(i.e.,corticosteroid-sparing)was7.5mg/day(range0to10mg/
day), and the median acceptable dose of topical prednisolone
acetate 1% was 2 drops/day (range 1 to 6 drops/day).
The median efficacy ratings for each corticosteroid-sparing
treatment and anatomic location are shown in Table 1. Within
each anatomic location, respondents thought there were
significant differences between the effectiveness levels of
the seven drugs (P≤0.001). As for perceived differences in
the effectiveness of each drug within a specific anatomic
location, only methotrexate had a statistically significant
difference. Respondents considered methotrexate to be only
somewhat effective for treating patients with intermediate,
posterior, and panuveitis, but mostly effective for those with
anterior uveitis (P≤0.001). This perceived difference in
effectiveness was reflected in the favorability ratings for
methotrexate, which were 62% for anterior, 44% for
intermediate, and 22% for posterior and panuveitis (Table 2).
Adalimumab was considered to be mostly effective for
patients with intermediate, posterior, and panuveitis, and
very effective for anterior uveitis (P=0.04). Similarly,
reported effectiveness ratings for cyclosporine were higher
in intermediate and posterior/panuveitis compared to anterior
uveitis (P=0.08). Only 20% responded favorably concerning
the use of cyclosporine in patients with anterior uveitis,
while 38% and 44% assigned a favorable rating for its use in
intermediate and posterior/panuveitis, respectively. Inflixi-
mab had the highest overall favorability ratings for effec-
tiveness (82%, 69%, 71% for anterior, intermediate, and
posterior/panuveitis, respectively) while azathioprine had the
lowest (29%, 31%, 33%).
Approximately 60% of respondents believe that metho-
trexate is more effective when administered subcutaneously
compared to by mouth. However, of patients prescribed
methotrexate doses of 20 mg/week and 25 mg/week, only
an average of 19% and 25%, respectively, were placed on
subcutaneous treatment. The mean maintenance dose of
methotrexate used was 18.5 mg weekly (range 7.0 to
25.0 mg weekly).
Used vs. preferred immunomodulatory therapy
The majority of respondents reported that methotrexate was
their most commonly used initial corticosteroid-sparing
treatment for noninfectious uveitis in all three anatomic
subgroups, followed by mycophenolate mofetil (85% vs. 6%
for anterior, P<0.001; 57% vs. 22% for intermediate, P=
0.002; 37% vs. 27% for posterior/panuveitis, P=0.49) (see
Fig. 1). Azathioprine, cyclophosphamide, and infliximab
were rarely or never used as initial corticosteroid-sparing
treatment, and none of the respondents listed adalimumab as
being used for initial treatment for any anatomic subgroup.
When asked about a scenario where cost and availability
of therapies were not an issue, 55% still reported that
methotrexate was their most preferred initial corticosteroid-
sparing treatment for anterior uveitis, followed by 20% for
mycophenolate mofetil (P=0.003). For intermediate and
posterior/panuveitis, however, mycophenolate mofetil was
most frequently preferred, followed by methotrexate (35%
vs. 24% for intermediate, P=0.45; 42% vs. 18% for
posterior/panuveitis, P=0.04). Some respondents reported
that they would prefer to use infliximab (10% anterior, 19%
intermediate, 18% posterior/panuveitis) and adalimumab
(13% anterior, 11% intermediate, 11% posterior/panuveitis)
as initial treatment in each subgroup. Worth estimates based
on ranking data indicate that methotrexate and mycophe-
nolate mofetil are consistently ranked first or second overall
in all scenarios, while cyclosporine, azathioprine, adalimu-
mab, and infliximab are clustered in the middle and
cyclophosphamide is consistently ranked last. The exact
order of treatment use and preference fluctuated depending
on anatomic location (Table 3).
Reasons immunomodulatory therapies are not prescribed
Respondents indicated that they might choose not to
prescribe each of the drugs for different reasons (Fig. 2).
The most common reason not to prescribe methotrexate or
azathioprine was concern about effectiveness (42% and
36%, respectively), although there was also some concern
Table 1 Median effectiveness ratings
a of immunomodulatory treatments
MTX MMF AZA CSA CTX INF ADA
Anterior 3 3 2 2 4 4 4 <0.001
Intermediate 2 3 2 2.5 4 3 3 <0.001
Posterior/panuveitis 2 3 2 3 4 3.5 3 <0.001
<0.001 0.44 0.79 0.08 0.87 0.47 0.04 P value
MTX methotrexate, MMF mycophenolate mofetil, AZA azathioprine, CSA cyclosporine, CTX cyclophosphamide, INF infliximab, ADA
adalimumab
aRespondents were asked to rate the effectiveness of each immunomodulatory therapy by anatomic subtype on a four-point scale (1=not effective,
2=somewhat effective, 3=mostly effective, 4=very effective)
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not to prescribe mycophenolate mofetil included cost
(40%), lack of long-term data on its use (13%), and
safety/tolerability (13%). The primary concern with using
cyclosporine or cyclophosphamide was safety/tolerability
(44% and 80%), but other reasons not to prescribe
cyclosporine included effectiveness (38%) and cost (13%).
The most common reason not to prescribe infliximab and
adalimumab was cost (62% and 56%, respectively). Other
prominent concerns for these biologic drugs included a lack
of long-term data (24% and 29%), safety/tolerability (22%
and 20%), and difficulty of administration (38% and 13%).
Discussion
Our results indicate that within each anatomic location,
there are significant differences in the perceived effective-
ness of corticosteroid-sparing treatments for controlling
ocular inflammation and allowing a successful corticoste-
roid taper.
Though they do not receive the highest favorability
ratings for effectiveness, the most commonly used and most
preferred drugs are from the antimetabolite class. Respond-
ents indicate that the long-used methotrexate is their most
common first choice corticosteroid-sparing therapy for all
anatomic locations of uveitis, with only mild concerns for
safety and tolerability. Even given the choice of any other
drug disregarding cost and availability, most would still
prefer to prescribe methotrexate for anterior uveitis.
Methotrexate, however, was the only drug in which there
was a significant difference in effectiveness ratings by
anatomic location. For intermediate and posterior/panuvei-
tis, respondents would prefer to use mycophenolate mofetil;
the main reason for not prescribing mycophenolate initially
seems to be cost. These trends were seen when looking at
Fig. 1 Histograms showing proportions of respondents, with 95%
onfidence intervals, ranking each treatment as most commonly used or
most preferredif cost andavailabilitywerenot anissue. MTX methotrexate,
MMF mycophenolate mofetil, AZA azathioprine, CSA cyclosporine, CTX
cyclophosphamide, INF infliximab, ADA adalimumab
Table 2 Favorability ratings of immunomodulatory therapies
MTX MMF AZA CSA CTX INF ADA
Favorable
a
Anterior 28 (62%) 24 (53%) 13 (29%) 9 (20%) 21 (47%) 37 (82%) 33 (73%)
Intermediate 20 (44%) 27 (60%) 14 (31%) 17 (38%) 24 (53%) 31 (69%) 26 (58%)
Posterior/panuveitis 10 (22%) 24 (53%) 15 (33%) 20 (44%) 32 (71%) 32 (71%) 25 (56%)
No opinion
Anterior 0 (0%) 7 (16%) 19 (42%) 16 (36%) 20 (44%) 5 (11%) 10 (22%)
Intermediate 1 (2%) 4 (9%) 13 (29%) 11 (24%) 17 (38%) 7 (16%) 12 (27%)
Posterior/panuveitis 1 (2%) 2 (4%) 11 (24%) 7 (16%) 9 (20%) 7 (16%) 16 (36%)
MTX methotrexate, MMF mycophenolate mofetil, AZA azathioprine, CSA cyclosporine, CTX cyclophosphamide, INF infliximab, ADA
adalimumab
aRating question responses of “mostly effective” or “very effective” were considered favorable. Respondents could also indicate if they had no
opinion for a particular combination
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treatments and when evaluating the full ranking data using
a Bradley–Terry model. This is a well-developed method of
rank-ordering items based on how each respondent ranks
each item in relation to the others, and may provide a more
relevant estimate of the relative usage and preference within
our survey population by incorporating more in-depth
information [6].
Even with the recent availability of generic mycopheno-
late mofetil, the cost per month is still more than double
that of methotrexate. According to Medicare reimbursement
rates, a 1-month supply of maintenance dose methotrexate
(25 mg per week) costs $50.55, and an equivalent supply of
generic mycophenolate mofetil (1 g twice a day) costs
$118.50 [7]. Retrospective studies by the Systemic Immu-
nosuppressive Therapy for Eye Diseases Cohort Study
Research Group, the largest such studies to date, have
reported corticosteroid-sparing success rates at 6 months
with methotrexate and mycophenolate for posterior/panu-
veitis at 21% and 41%, respectively [8, 9]. Another study,
comprised mostly of patients with posterior/panuveitis,
reported success rates of 42% with methotrexate compared
to 79% with mycophenolate mofetil [10]. There have been
no controlled trials comparing methotrexate and mycophe-
nolate mofetil for any anatomic location to confirm the
differences found in retrospective studies. Azathioprine, the
third antimetabolite option, was the least popular of the
three among our respondents. Published retrospective
Fig. 2 Histogram annotated
with percentage of respondents,
and 95% confidence intervals,
citing each reason for not pre-
scribing specific immunomodu-
latory therapies. MTX
methotrexate, MMF mycophe-
nolate mofetil, AZA azathio-
prine, CSA cyclosporine, CTX
cyclophosphamide, INF
infliximab, ADA adalimumab
Table 3 Overall rankings by anatomic location of uveitis and corresponding worth estimates
a
Rank Anterior Intermediate Posterior/pan
Used Preferred Used Preferred Used Preferred
1 MTX (0.60) MTX (0.30) MTX (0.24) MMF (0.23) MMF (0.21) MMF (0.22)
2 MMF (0.13) MMF (0.22) MMF (0.21) MTX (0.20) MTX (0.19) MTX (0.18)
3 INF (0.07) INF (0.14) AZA (0.13) INF (0.16) AZA (0.14) INF (0.15)
4 AZA (0.07) ADA (0.13) CSA (0.13) ADA (0.13) CSA (0.14) ADA (0.15)
5 ADA (0.06) AZA (0.10) INF (0.13) AZA (0.12) INF (0.13) CSA (0.12)
6 CSA (0.05) CSA (0.07) ADA (0.11) CSA (0.11) ADA (0.11) AZA (0.11)
7 CTX (0.02) CTX (0.04) CTX (0.05) CTX (0.05) CTX (0.08) CTX (0.07)
MTX methotrexate, MMF mycophenolate mofetil, AZA azathioprine, CSA cyclosporine, CTX cyclophosphamide, INF infliximab, ADA adalimumab
aCalculated using a Bradley–Terry model: represent what fraction of overall worth could be assigned to each treatment and are used to estimate an
overall ranking (e.g., based on the collective rankings of the respondents, methotrexate could be assigned 60% of the collective preference as the
most used initial treatment for anterior uveitis)
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methotrexate for uveitis, but discontinuations due to safety
and tolerability may be more frequent [9–12]. Azathioprine
is also widely used in rheumatologic diseases and organ
transplantation. Randomized trials comparing methotrexate
to azathioprine have shown similar effectiveness for
treating ANCA-associated vasculitis [13] and myasthenia
gravis [14], and mixed results in rheumatoid arthritis with
one small trial showing similar effectiveness [15] and
another showing greater effectiveness with methotrexate
[16]. Mycophenolate mofetil was shown to be more
effective than azathioprine in a randomized trial of patients
with Crohn’s disease [17] and for cardiac transplantation
[18], but trials in lupus nephritis [19] and renal transplan-
tation [20] found no significant differences.
Despite being the least used and least preferred as first-
line corticosteroid-sparing treatment, the biologic drugs
adalimumab and infliximab and the alkylating agent
cyclophosphamide received the overall highest effective-
ness ratings based on both medians and percent of
respondents giving a favorable response. Actual use and
preference, however, do not match these reported beliefs. In
fact, adalimumab, infliximab, and cyclophosphamide are
infrequently used and preferred as initial corticosteroid-
sparing treatment, even if cost and availability are not an
issue. In the case of adalimumab and infliximab, respond-
ents cited a number of reasons not to prescribe these
treatments, including cost, insufficient long-term data,
concerns with safety and tolerability, and difficulty of
administration. Adalimumab is given by subcutaneous
injections and infliximab by intravenous infusions. Despite
the overwhelming opinion that cyclophosphamide is effec-
tive, it was the least preferred drug, primarily due to
concern for the safety of the patient. Cyclophosphamide has
been associated with an increased risk of malignancy,
infertility, and other undesirable side effects, so this finding
was not surprising [21]. Cyclosporine, a calcineurin
inhibitor, was not commonly used and rarely preferred as
first-line corticosteroid-sparing therapy because of safety
and tolerability concerns and some doubt as to its
effectiveness. Previous publications report widely varying
rates of success with cyclosporine for uveitis, and there is
evidence of high rates of side effects including nephrotox-
icity [22].
This study does have limitations. It is possible that those
who chose to participate in the survey are somehow
different from those who did not, which would affect the
generalizability of our results to all uveitis specialists or
even to the members of the listservs as a whole. The sample
size raises the question of whether the responses collected
in this study reflect actual practice patterns of uveitis
specialists, though studies have shown surveys with similar
response rates (about 25%) to have comparable results to
those with higher response rates [23–25]. Increased sample
size could have been achieved by including a broader
sample of ophthalmologists in the study, but this would
have potentially compromised our goal of eliciting opinions
from uveitis specialists with extensive experience with
immunomodulatory therapy. The respondents were all
uveitis specialists, and the majority had greater than
10 years of practice experience, likely indicating the
respondent group had a high level of expertise in this
subject area. This is also highlighted by the fact that 100%
of respondents reported maximum oral corticosteroid doses
of 10 mg/day or less as acceptable maintenance levels,
demonstrating familiarity with the SUN guidelines on the
use of immunosuppressives [3]. This is in contrast with the
population of a recent survey focusing on corticosteroid use
in which steroid-sparing immunosuppressives were rarely
used and an average prednisone maintenance dose of
34 mg/day was reported [26]. In addition, as the vast
majority of the respondents in our survey practice in the
USA, reported practice patterns and preferences may be
specific to the USA and could be different in other
countries.
Perceptions of effectiveness and negative aspects of each
treatment could be affected in a number of ways. Although
general guidelines for the use of immunomodulatory
treatment of noninfectious uveitis have been established,
uveitis specialists may differ in the way they use each
treatment (varying maintenance doses, etc). They may also
treat patients with varying disease severities and etiologies
of uveitis, which could affect perceptions about each
treatment. It is also important to note that this survey
reported usage and preferences based on anatomical
location of inflammation rather than any associated disease
entity. For patients with severe uveitis-related complications
or a known associated inflammatory disease such as
juvenile idiopathic arthritis or Behcet’s, the nature of the
results may have been different. Other factors such as co-
management with a rheumatologist and age of the patient
population may also affect practice patterns.
Additionally, not all immunomodulatory drugs currently
used to treat uveitis were included in the survey; omitted
treatments include the calcineurin inhibitors tacrolimus and
sirolimus, the alkylating agent chlorambucil, and newer
biologic agents such as golimumab or certolizumab.
Etanercept was also not included; though etanercept has
been commercially available since 1999 and is used to treat
various systemic inflammatory conditions, a number of
studies have indicated that this particular TNF-alpha
inhibitor is likely not effective for controlling ocular
inflammation [27–29]. There was initially some concern
in the rheumatology literature that etanercept may even
induce ocular inflammation, but more recent findings
support the continued use of etanercept therapy for
26 J Ophthal Inflamm Infect (2012) 2:21–28inflammatory diseases with the caveat that patients devel-
oping uveitis may require a change in treatment regimen
[30]. We chose to include treatments which have been most
commonly reported in the literature to ensure that most
respondents would have some experience with each,
making comparisons between them possible.
Despite potentially mitigating factors, the results of this
survey were striking. They raise questions that warrant
further study, including the possibility of variable effec-
tiveness by anatomic location for some treatments, and also
highlight factors that uveitis specialists feel limit the
practical use of each immunomodulatory treatment. These
results may help guide future research comparing treatment
effectiveness for initial corticosteroid-sparing therapy in
noninfectious uveitis.
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